Chicago-based AbbVie announced plans for a strategic collaboration to develop a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator compound licensed from the Cystic Fibrosis Foundation.
A Vertex triple-combination treatment for cystic fibrosis hit the mark in two Phase III trials, setting the stage for the company to secure approval for another treatment for the life-shortening genetic disease that affects approximately 75,000 people in North America, Europe and Australia.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio.
Boston-based Proteostasis Therapeutics announced positive preliminary data from the ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis. Despite being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.
An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.
Privately held Celtaxsys Inc. said a mid-stage trial testing the company’s experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.
Shares of Galapagos NV fell after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration.
An experimental triple combination treatment for cystic fibrosis landed Vertex Pharmaceuticals at the top of EvaluatePharma’s “World Preview 2018” list.